Home > Vol 16, No 3 (2020) > Akhilgova
Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction
Z. M. Akhilgova, I. I. Almazova, N. K. Gabitova, E. A. Kotaeva, A. G. Avtandilov
https://doi.org/10.20996/1819-6446-2020-05-05
Aim. To assess the effect of combination therapy (perindopril, indapamide, amlodipine) on vascular stiffness and endothelial function in patients with heart failure with preserved ejection fraction (HFpEF).
Material and methods. Patients with HFpEF (n=30) were included in a nonrandomized, uncontrolled trial. All patients had a comprehensive examination: a six-minute walk test to determine exercise tolerance, echocardiography, determination of the diameter of the brachial artery with an assessment of its endothelium-dependent vasodilation (EDVD). Photoplethysmography and compression oscillometry were also carried out to assess the stiffness characteristics of vessels of various calibers and the determination of the cardio-ankle vascular index. Patients were examined initially and 16 weeks after the combination therapy order (perindopril 10 mg/day, indapamide 2.5 mg/day, amlodipine 5 mg/day).
Results. The data obtained during therapy shows improvement of the endothelial function for all patients: the initial EDVD was 8.5%, by the end of the observation period it increased to 11.4% (p=0.007). A significant decrease in the systemic vascular resistance from 2591 dyn*cm-5 to 2380 dyn*cm-5 (p=0.03) and in the level of specific peripheral resistance from 32.9 dyn/sec/cm-5 to 28.5 dyn/sec/cm-5 (p=0.0051). The stiffness indices of small resistive vessels also decreased: vascular stiffness index from 10.2±2.2 m/sec to 8.4±2.5 m/sec (p<0.0001) and pulse wave reflection index from 70.2±13.5% to 61.9±14.7% (p=0.0011). Cardio-ankle vascular index (CAVI) initially amounted to 9.2±1.3 and decreased by the end of the observation period during treatment to 8.3±1.1 (p=0.0003). The pulse blood pressure was significantly decrease from 71.31±15.5 mm Hg to 64.5±12.9 mm Hg (p=0.0048) and there was a tendency to decrease in pulse wave velocity from 808 cm/sec to 730 cm/sec.
Conclusion. The results of the study showed a statistically significant improvement in the elastic component of small resistive and major vessels, the endothelial function. The obtained results prove a decrease in the stiffness characteristics of blood vessels during the combination therapy.
This suggests that the combination of drugs with a different mechanism of action improves not only the state of the endothelium and its function, but also significantly reduces the stiffness of the great vessels, restores the microcirculatory support of the interstitium of the myocardium and vascular wall in patients with HFpEF and leads to an improvement in the clinical status of patients with this syndrome.
heart failure with preserved ejection fraction, treatment, vascular wall stiffness, endothelial function, microcirculation
Z. M. Akhilgova
Russian Medical Academy of Continuous Professional Education
Zarina M. Akhilgova - MD, Post-Graduated Student, Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.
Barrikadnaya ul. 2/1, Moscow, 123993.
I. I. Almazova
Ilda I. Almazova - MD, PhD, Assistant, Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.
N. K. Gabitova
City Clinical Hospital named after V.V. Veresaev
Nadezhda Kh. Gabitova - MD, PhD, Head of Cardiology Department №11, City Clinical Hospital named after V.V. Veresaev.
Lobnenskaya ul. 10, Moscow, 127411.
E. A. Kotaeva
City Clinical Hospital named after S.P. Botkin
Elena A. Kotaeva - MD, PhD, Head of Cardiology Department №5, City Clinical Hospital named after S.P. Botkin.
Botkinskiy pr-d 5, Moscow, 125284.
A. G. Avtandilov
Alexander G. Avtandilov - MD, PhD, Professor, Head of Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education.
Barrikadnayaul. 2/1, Moscow, 123993.
1. Dunlay S. M., Roger V.L., Redfield M.M. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591-602. DOI:10.1038/nrcardio.2017.65.
2. Levy B.I. How to Explain the Differences Between Renin Angiotensin System Modulators. Am J Hyper-tens. 2005;18(9 Pt 2):134S-141S. DOI:10.1016/j.amjhyper.2005.05.005.
3. Upadhya B., Taffet G.E., Cheng C.P., Kitzman D.W. Heart Failure with Preserved Ejection Fraction in the Elderly: Scope of the Problem. J Mol Cell Cardiol. 2015;83:73-87.. DOI:10.1016/j.yjmcc.2015.02.025.
4. Mohammed S.F., Hussain S., Mirzoyev S.A., et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550-9. DOI:10.1161/circulationaha.114.009625.
5. Crea F., Merz N. B., Beltrame J. F., et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 2017;38(7):473-7. DOI:10.1093/eur-heartj/ehw461.
6. Gevaert A.B., Boen Jente R.A., et al. Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Front Physiol. 2019;10:638. DOI:10.3389/fphys.2019.00638.
7. Kendall R.T., Feghali-Bostwick C.A. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. DOI:10.3389/fphar.2014.00123.
8. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 2016. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128.
9. Massie B.M., Carson P.E., M.D., McMurray J.J., et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med. 2008;359:2456-67. DOI:10.1056/NEJMoa0805450.
10. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6.
11. Yip G., Wang M., Wang T., et. al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573-80. DOI:10.1136/hrt.2007.117978.
12. Akhilgova Z.M., Kurkina M.V., Dzhioeva Z.R., et al. Diagnosis and the debatable issues of the treatment of heart failure with preserved ejection fraction. Cardiosomatics 2018;4:32-37 (In Russ.).
13. De Ciuceis C., Salvetti M., Paini A., et al. Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension. Intern Emerg Med. 2017;12(7):963-74. DOI:10.1007/s11739-017-1696-7.
14. Ganado P., Ruiz E., M. Del Rio et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. European Journal of Pharmacology. 2001;428(1):19-27. DOI:10.1016/S0014-2999(01)01275-4.
15. Janie М., Lunder М., Sabovic М. Arterial Stiffness and Cardiovascular Tcerapy. Biomed Res Int. 2014;2014:621437. DOI:10.1155/2014/621437.
16. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25. DOI:10.1161/CIRCULATIONAHA.105.595496.
17. Ferguson J.M., Minas J., Siapantas S., et al. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. Journal of Cardiovascular Pharmacology. 2008;51(6):590-95. DOI:10.1097/FJC.0b013e31817a8316.
18. Shahin Y., Khan J.A., Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18-33. DOI:10.1016/j.atherosclerosis.2011.12.005.
19. Kengne A.P., Czernichow S., Huxley R. et al. Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension 2009;54(2):399-404. DOI:10.1161/HYPERTENSIONAHA.109.133041.
For citations:
Akhilgova Z.M., Almazova I.I., Gabitova N.K., Kotaeva E.A., Avtandilov A.G. Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction. Rational Pharmacotherapy in Cardiology. 2020;16(3):377-382. (In Russ.) https://doi.org/10.20996/1819-6446-2020-05-05